A contact lens for treatment of ocular conditions, the contact lens comprising a composition comprising: an ester or amide of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a monohydric alcohol or an amine, wherein the majority of the anti-inflammatory lipid mediator is present in an ester form; wherein the anti-inflammatory lipid mediator: (a) is a prostaglandin selected from the group consisting of prostaglandin E1, prostaglandin E3, and combinations thereof, or (b) is a resolvin selected from the group consisting of resolvin E1, resolvin E2, resolvin D1, resolvin D2, resolvin D3, resolvin D4, and combinations thereof, or (c) is a lipoxin selected from the group consisting of lipoxin A4,lipoxin B4, and combinations thereof, or (d) comprises protectin D1, or (e) comprises 13-cis-retinoic acid, or (f) comprises an omega-three fatty acid, an omega-six fatty acid, or both, wherein the omega-three fatty acid is selected from the group consisting of: alpha-linolenic acid, stearidonic acid, eicosatetraenoic acid, eicosapentaenoic acid, docohexaenoic acid, docosapentaenoic acid, tetracosapentaenoic acid, and tetracosahexaenoic acid (Nisinic acid), and mixtures thereof; and the omega-six fatty acid is selected from the group consisting of linoleic acid, gamma-linolenic acid, eicosadienoic acid, dihomo-gamma-linolenic acid (DGLA), docosadienoic acid, adrenic acid, docosapentaenoic acid, or combinations thereof. an ester or amide of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a monohydric alcohol or an amine, wherein the majority of the anti-inflammatory lipid mediator is present in an ester form; wherein the anti-inflammatory lipid mediator: (a) is a prostaglandin selected from the group consisting of prostaglandin E1, prostaglandin E3, and combinations thereof, or (b) is a resolvin selected from the group consisting of resolvin E1, resolvin E2, resolvin D1, resolvin D2, resolvin D3, resolvin D4, and combinations thereof, or (c) is a lipoxin selected from the group consisting of lipoxin A4,lipoxin B4, and combinations thereof, or (d) comprises protectin D1, or (e) comprises 13-cis-retinoic acid, or (f) comprises an omega-three fatty acid, an omega-six fatty acid, or both, wherein the omega-three fatty acid is selected from the group consisting of: alpha-linolenic acid, stearidonic acid, eicosatetraenoic acid, eicosapentaenoic acid, docohexaenoic acid, docosapentaenoic acid, tetracosapentaenoic acid, and tetracosahexaenoic acid (Nisinic acid), and mixtures thereof; and the omega-six fatty acid is selected from the group consisting of linoleic acid, gamma-linolenic acid, eicosadienoic acid, dihomo-gamma-linolenic acid (DGLA), docosadienoic acid, adrenic acid, docosapentaenoic acid, or combinations thereof. (a) is a prostaglandin selected from the group consisting of prostaglandin E1, prostaglandin E3, and combinations thereof, or (b) is a resolvin selected from the group consisting of resolvin E1, resolvin E2, resolvin D1, resolvin D2, resolvin D3, resolvin D4, and combinations thereof, or (c) is a lipoxin selected from the group consisting of lipoxin A4,lipoxin B4, and combinations thereof, or (d) comprises protectin D1, or (e) comprises 13-cis-retinoic acid, or (f) comprises an omega-three fatty acid, an omega-six fatty acid, or both, wherein the omega-three fatty acid is selected from the group consisting of: alpha-linolenic acid, stearidonic acid, eicosatetraenoic acid, eicosapentaenoic acid, docohexaenoic acid, docosapentaenoic acid, tetracosapentaenoic acid, and tetracosahexaenoic acid (Nisinic acid), and mixtures thereof; and the omega-six fatty acid is selected from the group consisting of linoleic acid, gamma-linolenic acid, eicosadienoic acid, dihomo-gamma-linolenic acid (DGLA), docosadienoic acid, adrenic acid, docosapentaenoic acid, or combinations thereof.